Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Regeneron has been looking to switch patients ... This unique collaboration will see the Meningitis Flag — a powerful symbol of the global fight ag Roche beat first-quarter sales expectations ...

It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Data from an open-label extension of VISIONARY-MS support an association between gold nanocrystals and neuronal repair and remyelination in patients with stable multiple sclerosis and visual deficits, ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.46% to $590.00 Thursday, on what proved to be an all-around positive ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Regeneron Pharmaceuticals, Inc.REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...